Lundbeck A/S delivered revenue of DKK 18.2 billion ($2.62 billion) in 2022 supported by double digit growth for its four main products for neurological disorders. At the same time, it outlined plans for multiple investments, taking advantage of a period during which it expects a limited financial impact from patent expiries.
Long-term data from two Phase 3 trials of Cosentyx (secukinumab), an approved drug for plaque psoriasis and other inflammatory indications, have shown sustained efficacy and symptom improvement in patients with hidradenitis suppurativa (HS). HS is a recurrent skin disease causing abscesses that can lead to wounds and scarring. The two trials enrolled more than 1,000 patients in 40 countries.
The Roche Group has reported positive data from a Phase 3 programme of the monoclonal antibody crovalimab in people with paroxysmal nocturnal haemoglobinuria (PNH), a rare and life-threatening blood condition. PNH occurs when red blood cells are destroyed by the complement system, part of the innate immune system. Participants in the second of two studies had not been previously treated with complement inhibitors.
An antibody drug developed by Boehringer Ingelheim GmbH to prevent flares in generalised pustular psoriasis (GPP), a rare skin disease, has met its primary and key secondary endpoints in a Phase 2b trial of patients with the disease. Spesolimab (Spevigo) has already been approved for the treatment of the disease.
A new company in Scotland, UK has secured £2.4 million from KHAN Technology Transfer Fund I (KHAN-I) and existing investor Cumulus Oncology to pursue research into candidate molecules targeting DNA damage response. Nodus Oncology Ltd was founded in September 2022 to develop inhibitors of proteins involved in the repair of cells with DNA damage.
Evonetix Ltd, a UK synthetic biology company, has raised $24 million from a group of private investors to continue development of technology to enable the synthesis of DNA on a silicon chip. The latest funding is an extension of a Series B financing round that raised $30 million in 2020. The $54 million now available to the company will support development and commercialisation of the company’s semiconductor chips for multiple applications.
Diabetes drugs, especially the glucagon-like peptide-1 (GLP-1) medicines, drove sales at Novo Nordisk A/S to their highest level in five years giving a significant boost to both operating and net profits. Announcing its 2022 financial results on 1 February, the Danish company declared a total dividend for the year of DKK 12.40, up by 19% from a year earlier.
Net sales in 2022 were DKK 176.9 billion ($25.4 billion), up by 26%. At constant exchange rates the increase was 16%. Operating profit was DKK 74.8 billion, up by 28%, and represented 42.3% of sales.
With a strong contribution from the anti-inflammatory drug Dupixent and influenza vaccines, Sanofi SA was able to increase both sales and operating profit in 2022, paving the way for future investment. Sales were €42.9 billion in 2022, up by 13.9% from a year earlier. Measured in constant exchange rates, the increase was 7%. Operating profit was €8.5 billion, up by 5% on the basis of International Financial Reporting Standards.
Novartis spent 2022 executing a reorganisation that will see it spin off Sandoz, its generics and biosimilars business, into a separately incorporated Swiss company. The spin-off is set to take place in the second half of this year, the company has confirmed. This is the first of two pillars of a new structure that will see the parent company focus exclusively on proprietary medicines.
2022 was a time of structural change for GSK Plc, putting it on the path for a tighter focus on the development of specialty medicines and vaccines. The year was marked by the demerger of the company’s consumer healthcare business, the acquisition of two specialty medicine companies, and record sales for the shingles vaccine Shingrix.